Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

BACKGROUND: Second-generation FLT3-inhibitors (FLT3i) demonstrated single-agent composite CR rates (CRc) of 45–55% in patients with relapsed/refractory (R/R) FLT3-mutated AML in phase II/III trials. However, > 85% of patients treated were prior FLT3i naïve. The response rates to sequential FLT3i...

Descripción completa

Detalles Bibliográficos
Autores principales: Yilmaz, Musa, Alfayez, Mansour, DiNardo, Courtney D., Borthakur, Gautam, Kadia, Tapan M., Konopleva, Marina Y., Loghavi, Sanam, Kanagal-Shamanna, Rashmi, Patel, Keyur P., Jabbour, Elias J., Garcia-Manero, Guillermo, Pemmaraju, Naveen, Pierce, Sherry A., Ghayas, Issa, Short, Nicholas J., Montalban-Bravo, Guillermo, Takahashi, Koichi, Assi, Rita, Alotaibi, Ahmad S., Ohanian, Maro, Andreeff, Michael, Cortes, Jorge E., Kantarjian, Hagop M., Ravandi, Farhad, Daver, Naval G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542942/
https://www.ncbi.nlm.nih.gov/pubmed/33032648
http://dx.doi.org/10.1186/s13045-020-00964-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542942/
https://www.ncbi.nlm.nih.gov/pubmed/33032648
http://dx.doi.org/10.1186/s13045-020-00964-5

Ejemplares similares